Japanese scientists have developed a pioneering new brain imaging technique that can detect the build-up of destructive proteins linked to Alzheimer's disease. It could lead to new ways of diagnosing the condition and of testing the effectiveness of new drugs. The technology, reported in the journal Neuron, can identify inside a living brain clumps of a protein called tau that is closely linked to the disease. Alzheimer's Research UK said it was promising work.
Alzheimer's disease is a problem for researchers trying to come up with a cure. The brain starts to die years before any symptoms are detected, which means drugs are probably given too late. A diagnosis of Alzheimer's cannot be made with absolute certainty until a patient has died and their brain is examined. It is also not 100% clear what is the cause of the dementia and what are just symptoms. One protein, called tau, is very closely linked to the disease, with tangles of tau thought to be one way in which brain cells are killed.
The team, lead by the National Institute of Radiological Sciences in Chiba, used positron emission tomography to build a 3D picture of tau in the brain. The researchers developed a chemical that could bind to tau and then be detected during a brain scan.
Dr Magoto Higuchi, from the National Institute of Radiological Sciences in Japan, said: "Positron emission tomography images of tau accumulation... provide robust information on brain regions developing or at risk for tau-induced neuronal death." Dr Eric Karran, director of research at Alzheimer's Research UK, said: "This promising early study highlights a potential new method for detecting tau - a key player in both Alzheimer's and frontotemporal dementia - in the living brain." He also said that, with new drugs being developed to target tau, scans capable of visualising the protein inside the brain could be important for assessing whether treatments in clinical trials are hitting their target. If this method is proven to be effective, such a scan could also be a useful aid for providing people with an accurate diagnosis, as well as for monitoring disease progression.
Jack
Saturday, 21 September 2013
Saturday, 14 September 2013
Adult tissue reversed to embryo state
Spanish researchers say that for the first time the living tissue inside an animal has been regressed back into an embryonic state. They believe it could lead to new ways of repairing the body, for example after a heart attack. However, the study showed that the technique led to tumours forming in mice.
The transformation has already been carried out in a laboratory, by treating skin samples with a mix of chemicals or genetic modification. Now scientists at the Spanish National Cancer Research Centre in Madrid have achieved the same results inside an animal. Lead researcher Prof Manuel Serrano said: "It is a surprising result, this was not expected, most of us thought that it would be impossible." The research group used genetically modified mice to switch on, when they were given a specific drug, production of four chemicals shown to reverse a tissue's destiny in the laboratory. Tissues were successfully transformed back into an embryonic state, but without further direction they rapidly developed into tumours.
Prof Robin Ali, from the Institute of Ophthalmology in London, is using stem cell technology to rebuild the retina to restore sight. He said the "ultimate goal" would be some treatment that could regenerate the back of the eye, but he also said that it was a long way off. He added: "This is a really elegant study with important implications for the field. It will be a monumental task to prove this is safe, as what you're doing is innately dangerous, but it is exciting as it's potentially a new strategy for regenerative medicine." The technique was able to turn back the clock further than any other stem cell technology, including stem cells taken from an embryo. Previous techniques produce stem cells that make the tissues found in the body; this study could also make those needed to support an embryo in the womb, such as the placenta.
Prof Robin Lovell-Badge, from the MRC's National Institute of Medical Research, said that he could not see this technique leading directly to therapies, but rather improving scientific understanding. He commented: "To me the interesting thing was the evidence that the cells correspond to an earlier stage of development." He also said that, if it can be repeated with human cells, it could have important research implications such as understanding the placenta and how to help maintain a pregnancy.
Jack
The transformation has already been carried out in a laboratory, by treating skin samples with a mix of chemicals or genetic modification. Now scientists at the Spanish National Cancer Research Centre in Madrid have achieved the same results inside an animal. Lead researcher Prof Manuel Serrano said: "It is a surprising result, this was not expected, most of us thought that it would be impossible." The research group used genetically modified mice to switch on, when they were given a specific drug, production of four chemicals shown to reverse a tissue's destiny in the laboratory. Tissues were successfully transformed back into an embryonic state, but without further direction they rapidly developed into tumours.
Prof Robin Ali, from the Institute of Ophthalmology in London, is using stem cell technology to rebuild the retina to restore sight. He said the "ultimate goal" would be some treatment that could regenerate the back of the eye, but he also said that it was a long way off. He added: "This is a really elegant study with important implications for the field. It will be a monumental task to prove this is safe, as what you're doing is innately dangerous, but it is exciting as it's potentially a new strategy for regenerative medicine." The technique was able to turn back the clock further than any other stem cell technology, including stem cells taken from an embryo. Previous techniques produce stem cells that make the tissues found in the body; this study could also make those needed to support an embryo in the womb, such as the placenta.
Prof Robin Lovell-Badge, from the MRC's National Institute of Medical Research, said that he could not see this technique leading directly to therapies, but rather improving scientific understanding. He commented: "To me the interesting thing was the evidence that the cells correspond to an earlier stage of development." He also said that, if it can be repeated with human cells, it could have important research implications such as understanding the placenta and how to help maintain a pregnancy.
Jack
Friday, 6 September 2013
Ovarian cancer gene found in mice
Scientists in the UK have found a gene that, if faulty, may increase the risk of ovarian cancer. According to a new study, mice lacking the gene were twice as likely to develop ovarian tumours, as well as showing signs of infertility. Scientists at the London Research Institute, Cancer Research UK, say that if the gene has a similar role in humans it could lead to new screening tests. The gene that was being looked at in the study is known as Helq, and is involved in repairing damaged DNA.It was discovered that mice lacking the gene were twice as likely to develop ovarian tumours compared with those with a normal copy. Dr Simon Boulton, senior author from Cancer Research UK's London Research Institute, said: "Our findings show that if there are problems with the Helq gene in mice it increases the chance of them developing ovarian and other tumours. This is an exciting find because this might also be true for women with errors in Helq, and the next step will be to see if this is the case." He went on to say: "If it plays a similar role in humans, this may open up the possibility that, in the future, women could be screened for errors in the Helq gene that might increase their risk of ovarian cancer."
Ovarian cancer is the fifth most common cancer in women in the UK; each year about 7,000 women are diagnosed with the disease and about 4,300 die from it. The lifetime risk of a woman developing ovarian cancer is about 2%, but this may be higher in women with a strong family history of ovarian cancer, breast cancer, or both.
Dr Julie Sharp, Cancer Research UK's senior science information manager, said the study pulled together clues from a series of experiments building a picture of cell faults that could lead to ovarian cancer in women. She said: "Ovarian cancer can be hard to diagnose early and treat successfully so the more we know about the causes of the disease, the better equipped we will be to detect and treat it."
Jack
Subscribe to:
Posts (Atom)